Dihydroartemisinin piperaquine

DRUG15 trials

Sponsors

Armed Forces Research Institute of Medical Sciences, Thailand, Sabah Ahmed Omar, University of Bamenda, Jhpiego, Liverpool School of Tropical Medicine

Conditions

Drug Resistant Malaria Due to Plasmodium FalciparumHIV/AIDS Malaria Pregnancy and ChildbirthMalariaMalaria PaediatricsMalaria FalciparumMalaria InfectionMalaria PreventionMalaria, Falciparum

Early Phase 1

Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy

Not yet recruitingNCT07021430

University of North Carolina, Chapel HillMalaria Prevention

Start: 2026-04-01End: 2028-04-01Target: 300Updated: 2026-02-17

Phase 3

Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya

Sabah Ahmed OmarMalaria

Start: 2013-04-30End: 2015-07-31Target: 2100Updated: 2013-10-08

Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

CompletedNCT02974348

University of BamendaDrug Resistant Malaria Due to Plasmodium Falciparum

Start: 2013-01-31End: 2014-10-31Updated: 2016-11-29

Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia

CompletedNCT04844099

Liverpool School of Tropical MedicineMalaria, Sickle Cell Anemia in Children

Start: 2021-04-09End: 2023-07-12Updated: 2023-09-13

OPTIMAL DP dosing for malaria preventive treatment in Malawian infants

Active, not recruitingPACTR202211575727659

Liverpool School of Tropical MedicineMalaria Paediatrics

Start: 2022-11-01Target: 220Updated: 2026-01-27

SAFIRE: Safety of Antimalarials in the FIRst Trimester

RecruitingPACTR202505891635396

Liverpool School of Tropical MedicineMalaria

Start: 2025-05-16Target: 1510Updated: 2026-01-27

Phase 4

Therapeutic Efficacy Studies (TES) of antimalarial

RecruitingPACTR201811640750761

United States Agency for International DevelopmentMalaria

Start: 2018-03-01Target: 1000Updated: 2026-01-27

Malaria Therapeutic Efficacy Study (TES) Kenya

CompletedNCT04767191

JhpiegoUncomplicated Malaria

Start: 2021-03-15End: 2022-12-18Updated: 2023-11-01

Evaluation of the efficacy of Artemisinin Combination therapy in Kenya

Active, not recruitingPACTR202404710340979

Kenya Medical Research InstituteMalaria

Start: 2024-05-01Target: 330Updated: 2026-01-27

Monitoring chemosensitivity of first-line antimalarial drugs for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 12 years in Burkina Faso

RecruitingPACTR202405899935406

Secretariat Permanent pour elimination du PaludismeMalaria

Start: 2024-05-01Target: 1386Updated: 2026-01-27

Perennial Malaria Chemoprevention in the Malaria Vaccine Era

Not yet recruitingNCT07322068

Stanford UniversityMalaria, Falciparum

Start: 2026-09-30End: 2033-06-30Target: 1290Updated: 2026-01-07

Unknown Phase

Malaria Active Epidemiology and Treatment Study

CompletedNCT01280162

Armed Forces Research Institute of Medical Sciences, ThailandMalaria

Start: 2010-09-30End: 2012-12-31Updated: 2021-03-03

IMPROVE DDI sub-study: Dihydroartemisinin piperaquine (DP)-Dolutegravir-based ART drug-drug interactions in pregnancy

Active, not recruitingPACTR201910580840196

Liverpool School of Tropical MedicineHIV/AIDS Malaria Pregnancy and Childbirth

Start: 2019-10-14Target: 22Updated: 2026-01-27

Evaluation of population diversity of Plasmodium falciparum isolates from children with uncomplicated infection during the adoption of artemisinin-based combination therapy in Nigeria

Active, not recruitingPACTR202106708800075

Kazeem AkanoMalaria

Start: 2021-06-21Target: 75Updated: 2026-01-27

IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding

Active, not recruitingNCT06870344

University of North Carolina, Chapel HillMalaria Falciparum, Malaria Infection

Start: 2025-03-12End: 2026-07-01Target: 36000Updated: 2025-08-08

Related Papers

A pharmacokinetic randomised interventional study to optimise dihydroartemisinin-piperaquine dosing for malaria preventive treatment in Malawian infants: A protocol for the OPTIMAL study

Wellcome Open Research2025-10-01

Weekly dihydroartemisinin-piperaquine versus monthly sulfadoxine-pyrimethamine for malaria chemoprevention in children with sickle cell anaemia in Uganda and Malawi (CHEMCHA): a randomised, double-blind, placebo-controlled trial.

2024-12-204 citations

Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-controlled superiority trial.

2023-04-055 citations

Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.

2022-11-145 citations

Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda.

2021-12-2446 citations

Genetic diversity of Plasmodium falciparum and genetic profile in children affected by uncomplicated malaria in Cameroon

Malaria Journal2020-03-1866 citations

Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia

Antimicrobial Agents and Chemotherapy2017-02-1420 citations

Antibody profiles to plasmodium merozoite surface protein-1 in Cambodian adults during an active surveillance cohort with nested treatment study.

2016-01-086 citations

Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.

2015-04-12207 citations

Efficacy of Two versus Three-Day Regimens of Dihydroartemisinin-Piperaquine for Uncomplicated Malaria in Military Personnel in Northern Cambodia: An Open-Label Randomized Trial

PLoS ONE2014-03-2559 citations